Navigation Links
BioCryst Updates Peramivir Clinical Development Plan
Date:1/23/2008

he development and commercialization of forodesine HCl in markets across Europe, Asia, Australia and certain neighboring countries. In February 2007, BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.

Forward-looking statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by i.m. injection may not be correct, that HHS and the FDA may not agree with our analysis, that HHS may further condition, reduce or eliminate funding of the peramivir program, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in CTCL may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that Bio
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
2. BioCryst Provides Forodesine HCl Update
3. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
4. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
7. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
8. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... ROCKVILLE, Md. , May 20, 2013  Neuralstem, ... Eva Feldman , MD, PhD, principal investigator, presented ... neural stem cell (NSI-566) trial in the treatment of ... ,s disease) at the neuro diabetes special medical ... Friday. In a talk called "Recent Therapeutic Advances in ...
(Date:5/20/2013)... , May 20, 2013 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that ... offering a greater effect on quality of life ... Given the high level of subjectivity and variability ... interviewed thought leaders state that it is difficult ...
(Date:5/19/2013)... 20, 2013  Whole-cell pertussis vaccines were more effective ... a large recent outbreak, according to a new Kaiser ... vaccines, also called DTwP, were available from the 1940s ... ultimately led to the development of acellular pertussis vaccines, ... the United States had switched ...
Breaking Medicine Technology:Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4
... , , TITUSVILLE, ... U.S. Food and Drug Administration approved INVEGA(R) SUSTENNA(TM) (paliperidone ... treatment of schizophrenia in adults on Friday, July 31, ... antipsychotic approved in the U.S. for this use. Janssen((R)), ...
... NEW YORK, July 29 Grammy-Award winning artist and ... to create an exclusive (RED)ZONE seating section for his August 13th, ... Beginning July 29th, every purchase at select Gap stores in the ... shoppers to obtain one ticket in the reserved RED(ZONE) section for ...
Cached Medicine Technology:Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 2Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 3Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 4Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 5Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 6Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 7Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 8Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 9John Legend and Gap Join (PRODUCT)RED(TM) to Help Eliminate AIDS in Africa with Exclusive (RED)ZONE Seating at Madison Square Garden 2John Legend and Gap Join (PRODUCT)RED(TM) to Help Eliminate AIDS in Africa with Exclusive (RED)ZONE Seating at Madison Square Garden 3
(Date:5/20/2013)... Chicago, IL (PRWEB) May 20, 2013 ... of innovative cloud and on-premise business process ... version 6.0 of its next-generation integration solution. ... data integration solution that seamlessly automates business ... and reporting with meaningful business user interaction ...
(Date:5/20/2013)... HealthDay Reporter , , MONDAY, May 20 (HealthDay News) -- ... out in the late 1990s is more effective than ... contends. Teenagers who received four shots with the ... were 2 years old were significantly less likely to ... in California, compared to children who received all of ...
(Date:5/20/2013)... Mich. As high schoolers prepare for final exams, ... drug" -- a prescription stimulant or amphetamine -- to ... Michigan poll shows only one in 100 parents of ... used a study drug., Study drugs refer to stimulant ... hyperactivity disorder (ADHD); commonly prescribed medicines in this category ...
(Date:5/20/2013)... 20, 2013 Medicare Part D seniors ... citing lower costs, convenient access to pharmacies and other ... Associates released today by the Pharmaceutical Care Management Association ... million) are currently enrolled in plans with preferred networks. ... overall value of plans with preferred pharmacy networks,” said ...
(Date:5/20/2013)... It’s May which means it’s Bike Month! If ... out those dusty bikes and helmets. , Windsong Production's and ... in the office with Windsong Productions challenging ... pledged miles for the 4th Annual Million Mile Challenge. They ... , *insert battle prep montage* , This is all part ...
Breaking Medicine News(10 mins):Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 2Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 3Health News:Study: Older Whooping Cough Vaccine More Effective 2Health News:Study: Older Whooping Cough Vaccine More Effective 3Health News:1 in 10 teens using 'study drugs,' but parents aren't paying attention 2Health News:Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2
... raising chance of morphine overdose for baby , , FRIDAY, ... medicines containing codeine and metabolize the drug quickly may ... overdose, U.S. health officials said Friday. , The ... a report of the death of a 13-day-old breast-fed ...
... to handle the information, study suggests , , FRIDAY, Aug. ... becomes more commonplace, the impact of those findings on ... instance, some women who discover they have the BRCA ... breast cancer, choose to tell their children about it ...
... psychologists, Louise Hawkley and John Cacioppo, have been trying ... and diseases of aging, right down to the cellular ... of loneliness may be mild and unremarkable in early ... the scientists studied a group of college-age individuals and ...
... Are too many people now diagnosed as having depression? Two ... Gordon Parker, a psychiatrist from Australia says the current threshold ... low. He fears it could lead to a diagnosis ... says, normal to be depressed and points to his own ...
... over a million deaths every year, even though it has ... net (ITN) greatly reduces the chance of being bitten by ... arguments as to how best to increase the use of ... in Kenya, published in the latest issue of PLoS Medicine, ...
... radar of the immune system is by using IDO, an ... powerful regulatory T cells that turn down the immune response, ... barrier of regulatory T cells, or Tregs, but how ... David Munn, pediatric hematologist/oncologist at the Medical College of Georgia ...
Cached Medicine News:Health News:FDA Warns of Codeine Risk for Some Nursing Mothers 2Health News:FDA Warns of Codeine Risk for Some Nursing Mothers 3Health News:Many Parents Share Genetic Test Findings With Kids 2Health News:Loneliness is bad for your health 2Health News:Are too many people diagnosed as 'depressed?' 2Health News:Free distribution of insecticide-treated mosquito nets can save lives 2Health News:Tumors use enzyme to recruit regulatory T-cells and suppress immune response 2Health News:Tumors use enzyme to recruit regulatory T-cells and suppress immune response 3Health News:Tumors use enzyme to recruit regulatory T-cells and suppress immune response 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: